Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Gender disparities in the National Institutes of Health funding for gastrointestinal oncology. Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively ...
Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group PURPOSE: To characterize the clinical and biologic features of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results